🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Yi Yang clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Yi Yang as lead sponsor. Synced 26 Sep 2026
12Current trials
6Recruiting now
4Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Yi Yang is the lead sponsor of 12 current clinical trials in our China register. 6 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Levofloxacin, Levofloxacin simulant and Edaravone Dexborneol. The most-studied condition is Acute Ischemic Stroke.

ClinicalTrials.gov trials by status

  • Recruiting650%
  • Not yet open650%

Trials by phase

  • Not applicable1083%
  • Observational18%
  • Phase 418%
01

Clinical trials sponsored by Yi Yang

12 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Safety and Efficacy of Levofloxacin for Acute Ischemic Stroke
NCT05799326 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke
Not applicable Recruiting 2023-06 China
Safety and Efficacy of Remote Ischemic Conditioning Treatment for Community-based Essential Hypertension
NCT03945305 · ClinicalTrials.gov ↗ · Essential Hypertension
Not applicable Recruiting 2023-11 China
Application of Biomarkers in Neurological Diseases
NCT05881226 · ClinicalTrials.gov ↗ · Biomarkers
Observational Recruiting 2023-06 China
Effects of Remote Ischemic Conditioning on Blood Pressure in Older Patients With Hypertension
NCT05845905 · ClinicalTrials.gov ↗ · Essential Hypertension
Not applicable Recruiting 2023-05 China
iTBS for Acute Ischemic Stroke After Thrombectomy
NCT06941961 · ClinicalTrials.gov ↗ · Ischemic Stroke
Not applicable Recruiting 2025-04 China
Safety and Efficacy of Levofloxacin Combined With Intravenous Thrombolysis for Acute Ischemic Stroke
NCT05741905 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke
Not applicable Recruiting 2023-06 China
Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke
NCT06137300 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke
Not applicable Not yet open 2024-03 China
Effects of rTMS on the Anxiety State of Older Patients With GAD
NCT05883774 · ClinicalTrials.gov ↗ · Generalized Anxiety Disorder
Not applicable Not yet open 2024-12 China
Safety and Efficacy of Remote Ischemic Conditioning in Patients With Spontaneous Intracerebral Hemorrhage
NCT03484936 · ClinicalTrials.gov ↗ · Intracranial Hemorrhages
Not applicable Not yet open 2026-03 China
Efficacy and Safety of Plasma Adsorption Combined With EVT for AIS-LVO
NCT07042490 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke From Large Vessel Occlusion, Endovascular Thrombectomy
Not applicable Not yet open 2025-06 China
Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic Stroke
NCT06645522 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke
Phase 4 Not yet open 2024-10 China
Effectiveness of Digital Health Management on Patients With Head and Neck Vascular Stenosis
NCT05798013 · ClinicalTrials.gov ↗ · Head and Neck Vascular Stenosis
Not applicable Not yet open 2025-10 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Yi Yang trials

4 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Yi Yang trials

9 conditions
Acute Ischemic Stroke4Essential Hypertension2Generalized Anxiety Disorder1Intracranial Hemorrhages1Biomarkers1Acute Ischemic Stroke From Large Vessel Occlusion1Endovascular Thrombectomy1Head and Neck Vascular Stenosis1Ischemic Stroke1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China126

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Acute Ischemic Stroke

SponsorTrials
Capital Medical University14
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University7
Xuanwu Hospital, Beijing6
Nanfang Hospital, Southern Medical University4
Beijing Anzhen Hospital4
The First Affiliated Hospital of University of Science and Technology of China4
The First Affiliated Hospital of Zhengzhou University3
Xiang Luo3
Shanghai Pharmaceuticals Holding2
First Affiliated Hospital Xi'an Jiaotong University2

Sponsors with the most current trials registered for this condition.

06

Questions about Yi Yang trials

How many clinical trials does Yi Yang sponsor?

Yi Yang is the lead sponsor of 12 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Yi Yang trials recruiting?

Yes. 6 of its 12 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Yi Yang testing?

Its current trials name 4 drugs and biologicals as interventions. The most frequent are Levofloxacin (2), Levofloxacin simulant (2), Edaravone Dexborneol (1) and Urinary kallidinogenase (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.